Current Standard-of-Care Treatment for Patients With BCG-Unresponsive High-Risk NMIBC

Disitamab vedotin plus toripalimab showed significant survival benefits vs chemo in first-line HER2+ advanced urothelial carcinoma, with a manageable safety profile.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

The FDA issued an RTF for sBLA of nogapendekin alfa plus BCG for BCG-unresponsive NMIBC papillary disease, following prior positive feedback.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

A phase 3 trial showed neoadjuvant mitomycin C before TURBT in NMIBC patients was safe. While 12-month recurrence-free survival was similar to standard care, an 18-month trend suggested a possible delayed benefit.

ENVISION trial 18-month data show UGN-102 yielded a high initial complete response (79.6%) in recurrent low-grade intermediate-risk NMIBC, with 80.6% maintaining response. The gel formulation with mitomycin offers a nonsurgical chemoablation with favorable tolerability.